The patent expands the company's existing patent portfolio, which stands at ten previously granted or allowed patents, protecting multiple aspects of its proprietary liver disease diagnostic platform.
Having IP protection for HCC Panel in China is an important milestone for Glycotest, with the country having a notoriously high liver cancer death rate.
Glycotest also holds patents in the US, Europe, Japan and Australia covering the use of over 50 unique glycoprotein biomarkers and related assay technology for the diagnosis of liver cancers and other liver diseases.
In two studies, HCC Panel has shown that it has the potential to outperform the current dominant blood test regarding the early detection of liver cancer in patients with cirrhosis.
NetScientific holds an 87.5% stake in Glycotest, or 67% on a fully diluted basis.
"We are pleased to announce that Glycotest's IP portfolio will now also cover China, a highly significant market, which accounts for over 50% of worldwide deaths from liver cancer. We believe Glycotest's HCC panel will enable early detection of HCC and, once commercialised, will change the paradigm of care."
NetScientific shares jumped 2.8% to 56p early on Thursday.